Not only do these mutations help distinguish between WM and other similar hematologic malignancies like myeloma, but they are also predictive with regards to response rates to ibrutinib and other Bruton’s tyrosine kinase (BTK) inhibitors in WM. Here, BTK is linked to plasma cell myeloma.